|Bid||4.5900 x 1400|
|Ask||4.6100 x 800|
|Day's Range||4.4215 - 4.9500|
|52 Week Range||0.9000 - 10.2400|
|Beta (5Y Monthly)||0.73|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.00|
Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today announced additional positive pre-clinical results in its immuno-oncology program demonstrating efficacy of its live biotherapeutic product (LBP) consortium BMC128, this time in melanoma. In these studies, Biomica tested BMC128, which consists of four live bacterial strains, in a mouse model of melanoma.
Evogene Ltd. (NASDAQ: EVGN), (TASE: EVGN), a leading computational biology company today announced that it will hold virtual investor and analyst days, in both Hebrew and English, via Zoom webinars.
Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2020 with the U.S. Securities and Exchange Commission (the "SEC").